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ABSTRACT
Objectives: End-stage renal disease (ESRD) is a debilitating condition
resulting in death unless treated. Treatment options are transplantation and
dialysis. Alternative dialysis modalities are peritoneal dialysis (PD) and
hemodialysis (HD), each of which has been shown to produce similar
outcomes and survival. Nevertheless, the ﬁnancial implications of each
modality are different and these differences vary by country, especially in the
developing world. Changes in clinically appropriate dialysis delivery
leading to more efﬁcient use of resources would increase the resources
available to treat ESRD or other disabling conditions. This article outlines
the relative advantages of HD and PD and uses budget impact analysis to
estimate the country-speciﬁc, 5-year ﬁnancial implications on total dialysis
costs assuming utilization shifts from HD to PD in two high-income (UK,
Singapore), three upper-middle-income (Mexico, Chile, Romania), and
three lower-middle-income (Thailand, China, Colombia) countries.
Results: Peritoneal dialysis is a clinically effective dialysis option that can
be signiﬁcantly cost-saving compared to HD, even in developing countries.
Conclusions: The magnitude of costs associated with treating ESRD
patients globally is large and growing. PD is a clinically effective dialysis
option that can be used by a majority of ESRD patients and can also be
signiﬁcantly cost-saving compared to HD therapy. Increasing clinically
appropriate PD use would substantially reduce health-care costs and help
health-care systems meet ever-tightening budget constraints.
Keywords: chronic kidney disease, dialysis, economics, end-stage renal
disease, hemodialysis, modality selection, peritoneal dialysis.
Introduction
The global incidence of chronic kidney disease (CKD) continues
to rise. At the end of 1990 there were approximately 426,000
maintenance dialysis patients worldwide [1]. By the end of
2004 this number had climbed to nearly 1.4 million [2]. There
are ﬁve stages of CKD, each representing worsening degrees of
kidney failure. The ﬁfth and ﬁnal stage is a debilitating com-
plete, or near complete failure of kidney function. Treatment
options for patients with CKD stage 5, also called end-stage
renal disease (ESRD), are transplant and dialysis. In the absence
of kidney transplantation and without dialysis these patients
would die of uremia, many within a matter of weeks. Kidney
transplantation is generally recognized as the most clinically
effective and cost-efﬁcient treatment [3]. Nevertheless, not all
patients are medically suitable for transplantation and the
demand for kidneys far exceeds the supply, often rendering this
option unavailable. In light of this, dialysis remains the most
commonly employed treatment option for patients with ESRD.
At the end of 2004, only about 23% of ESRD patients world-
wide were living with a functioning kidney transplant and the
remaining 77% were on dialysis [2].
The 2004 global average prevalence for ESRD patients on
dialysis was 280 patients per million population, although there
were signiﬁcant regional variations. Prevalence was higher in
Japan (2045 per million) and North America (1505 per million)
than in the European Union (850 per million), Latin America
(380 per million), the Middle East (190 per million), Africa (70
per million) or Asia (70 per million, excluding Japan) [2].
By the year 2010 it is predicted that the global maintenance
dialysis populationwill approach or exceed twomillion [1,2]. The
costs of dialysis services to support this population are expected to
amount to $1.1 trillion for the decade 2001 to 2010 [1]. In the
USA alone, Medicare costs for dialysis in 2004 were $16.3 billion
[4].
Clearly, both the burden of illness and the resources needed
for treatment of patients on dialysis have been escalating despite
increasing pressures on health-care budgets. This, along with
worldwide increases in the prevalence of diabetes, hypertension,
and obesity, speaks to high—and growing—demand for dialysis
treatment on every health-care system in the world. The purpose
of this article is to outline the potential beneﬁts of changing the
relative use of HD and PD and to consider the extent to which
the mix of dialysis modalities employed to serve ESRD patients
might reduce the ﬁnancial burden of caring for this expanding
population and maximize the level of dialysis services that a ﬁxed
health-care budget is able to support.
Current Dialysis Options
Alternative dialysis modalities are hemodialysis (HD) and peri-
toneal dialysis (PD). HD may, in some cases, be performed at
home, but is most commonly performed in a dialysis center three
times per week, requiring the patient to travel to treatments
lasting on average 3 to 5 hours. In contrast, PD is usually per-
formed daily at home, and provides considerable ﬂexibility for
work and travel. Primary types of PD include continuous ambu-
latory peritoneal dialysis (CAPD) and automated peritoneal
dialysis (APD).
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Comparative Outcomes of Dialysis
Although many factors inﬂuence the selection of one dialysis
modality over another [5–9], absolute medical contraindications
for the use of either modality are few [10]. The effect of dialysis
modality on survival is a controversy that has been debated in the
literature for well over a decade [11–21]. Nevertheless, several
careful reviews of the literature have unveiled some common
themes, among them that utilization of PD as the initial dialysis
modality seems to offer a survival advantage compared to HD
early in therapy [12–18,20]. Eventually, though, the advantage
for PD levels off and mortality rates become roughly equivalent
with HD for several years. In the USA, 5-year survival for inci-
dent PD patients may have begun to exceed that for incident HD
patients as of the year 2000 [22,23].
The overall incidence of infection among PD patients is no
greater than among HD patients and studies have shown the
incidence of serious bloodstream infections to be lower in PD
than in HD, at least in some parts of the world [24–28]. In the
USA, the hospital admission rate because of dialysis-related
infections is lower in PD than in HD [29]. Finally, the clinical and
economic beneﬁts of preserving RRF are well documented
[30–37] and there is evidence that PD is associated with signiﬁ-
cant preservation of RRF compared to HD [32–34,38]. This may
explain in part the early survival advantage observed for patients
on PD.
Factors Inﬂuencing Modality Selection
A limited number of medical conditions constitute speciﬁc indi-
cations to select one dialysis modality over the other as the initial
treatment modality [39]. Absolute medical contraindications for
the use of PD in the USA include documented loss of peritoneal
function or extensive abdominal adhesions that limit dialysate
ﬂow, and uncorrectable mechanical defects that prevent effective
PD or increase the risk of infection, such as a surgically irrepa-
rable hernia or bladder extrophy. Conversely, PD may be pre-
ferred in patients who cannot tolerate HD for medical reasons,
such as congestive heart failure, ischemic heart disease, extensive
vascular disease or problematic vascular access.
In practice, a number of nonmedical factors may also inﬂu-
ence dialysis modality selection. Among these, ﬁnancial and
reimbursement issues have been identiﬁed as the most important
in any given country [8,9,40]. A recent review of the literature in
North America concluded that overall health-care costs for
patients receiving HD are between 22% and 52% higher than the
corresponding costs for patients receiving PD [41]. In general,
studies in Western Europe are in agreement with the North
American ﬁndings; a review of Western European literature
found that in-center HD ranged from about twice the cost of PD
in France to 30% more expensive than PD in Italy and the UK
[41]. In Eastern Europe, PD costs have been shown to be similar
or lower than HD costs [42,43]. In developing countries PD is
often perceived to be more expensive than HD because of rela-
tively low costs of labor and space and relatively high costs of
imported supplies [41,44]. Nevertheless, although few economic
evaluations of dialysis are available from developing countries,
recently reported data from China, Mexico, and Chile suggest
that PD is, in actuality, less expensive compared to HD [44–49].
Physician preferences can also inﬂuence modality selection.
Recent studies conducted in Canada, the USA and the
UK—countries with health systems very different from one
another—report that practicing nephrologists estimate the
optimal mix of HD to PD at about 65:35 (or 60:40, according to
nephrologists in the UK), where “optimal” is deﬁned as maxi-
mizing clinical outcomes [5,50,51]. Despite this, physicians and
nurses in some nations, including developed ones, may not have
had adequate training in PD and thus may be more comfortable
recommending HD [7,9].
Most studies suggest that PD offers similar quality of life
compared to HD [6,52–58] and that PD is associated with equal
or better treatment satisfaction compared to HD [59,60]. Several
studies have shown patients who are objectively educated about
dialysis modality options and given free choice more often
choose PD or other self-care dialysis than do uneducated patients
[61–66].
Social/cultural issues may inﬂuence utilization of dialysis
modalities as well. In Germany and Hong Kong, for instance,
many patients prefer in-center dialysis because of small living
spaces and the desire to not involve other family members [8].
Increased distance from a dialysis center has been associated with
increased use of PD in Canada, Latin America and the UK [8,64].
Culturally, most Japanese patients prefer to receive health care at
clinics or hospitals rather than at home (which drives utilization
of HD), but in Hong Kong, many patients are averse to needle
puncture (which drives utilization of PD) [8].
Underutilization of PD in Many Countries
Despite its clinical and economic advantages, nephrologists’
opinions that 35% to 40% use of PD would produce optimal
clinical outcomes and, in some cases, patient/social preference for
PD, the modality remains underutilized in many countries
around the world. The highest utilization of PD is in Mexico,
where an estimated 70% of prevalent dialysis patients were
treated with PD in 2004. New Zealand has the next highest PD
utilization rate at 43% [67]. Utilization of PD in most other
countries is well below these levels: worldwide at the end of 2004
an estimated 89% of dialysis patients were treated with HD and
only 11% were treated with PD [2].
Increasingly across the globe, ﬁnancial concerns and the avail-
ability of key clinical resources inﬂuence the delivery of all aspects
of medical care, including dialysis treatment for ESRD. Growing
ﬁnancial pressures obligate governments and other decision-
makers to grapple with how best to allocate health-care resources
for everyone in their charge, while at the same time balancing the
competing objectives of clinical need and cost containment [68].
Slowing the progression of CKD to ESRD is one strategy to save
lives and reduce the cost of treatment for dialysis. A complemen-
tary approach is to maximize the cost-efﬁciency of renal replace-
ment therapy wherever possible.
Wherever the systems cost of providing PD is lower than HD,
an increased use of PD would provide an opportunity to lower
overall ESRD treatment costs. We conducted an analysis to
explore the extent to which increased use of PD would lower
overall ESRD treatment costs in eight countries across the globe
and, in turn, maximize the level of dialysis services that a ﬁxed
health-care budget is able to support.
Methods
We used budget impact analysis to estimate how changes in the
mix of dialysis modalities would impact the trajectory of total
spending for dialysis services in eight countries. Budget impact
analyses are commonly used to estimate the ﬁnancial stream of
consequences related to the uptake and diffusion of health tech-
nologies to assess their affordability [69]. Increasingly, budget
impact analyses are sought out by those who manage and plan
health-care budgets, such as administrators of national or
regional health-care programs or private insurance plans.
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A Microsoft Excel-based model was developed to assess the
cumulative budget impact (payer’s perspective) of a shift in the
dialysis treatment modality mix. The model begins with point-
prevalent patient years at risk (acknowledging that the average
point-prevalent patient may receive fewer than 12 months of
dialysis treatment per year) in the baseline year and performs a
simple arithmetic forecast of current and future spending for
patients on dialysis up to a maximum of 5 years from baseline,
assuming that the mix of dialysis modality use shifts toward
greater use of PD over time. We used the model to estimate
impacts for two high-income (UK, Singapore), three upper-
middle-income (Mexico, Chile, Romania), and three lower-
middle-income countries (Thailand, China, Colombia) as deﬁned
by the World Bank. According to World Bank deﬁnitions, lower-
middle and upper-middle-income countries are all considered to
be developing countries.
Primary model inputs were derived from a variety of sources
as indicated in Tables 1 and 2. Cost data, in particular, were
drawn from published research conducted over different time
periods and using very different methodologies; as such, direct
comparisons of results between countries in this analysis are
inappropriate. Instead, the model estimates the potential
magnitude of country-speciﬁc savings assuming shifts toward
greater PD use in eight separate nations.
For the UK, total costs of dialysis, including drugs and trans-
portation, were obtained from a study of dialysis costs in the
Cardiff and Vale National Health Services Trust and six other UK
hospitals [70]. Using semi-structured interviews with nephrolo-
gists, head nurses, and business managers, these researchers iden-
tiﬁed the steps involved in delivering each modality and
estimated the costs associated with each step using published
ﬁgures or suppliers’ published price lists. For Singapore, cost data
represent average charges for outpatient HD and PD, estimated
based on government reimbursements for unsubsidized treat-
ment delivered in public, private, and Voluntary Welfare Orga-
nization sector facilities [71–73].
Estimates for Mexico include both direct (e.g., solutions,
drugs, lab tests, hospitalizations) and indirect (transportation,
lost productivity) costs of care. Cost input estimates for Chile are
based on a study by Pacheco et al examining direct (dialysis, iron
supplementation, erythropoiesis stimulating agents, hospitaliza-
tion) and indirect (workplace productivity, transportation) costs
of each modality, indexed to health-related quality of life [74].
For Romania, estimates represent government reimbursement
rates for PD and HD obtained from SofMedica, a local distribu-
tor of dialysis products in Romania. Health-care cost ﬁgures for
HD and PD in Thailand include lifetime costs of palliative care,
set-up costs for PD (e.g., peritoneal catheter implantation for PD,
arteriovenous graft for HD), annual maintenance costs, and costs
of treating comorbidities and complications, as well as direct and
indirect nonhealth-care costs (e.g., travel, time away from work)
paid by patients [75].
Reference costs for China were estimated using data from
dialysis centers in four hospitals (in Beijing, Shanghai, and
Changsa) in combination with detailed survey data collected
from 1061 ESRD patients. These estimates include direct medical
(dialysis, drug treatment for complications, laboratory, hospital-
izations), direct nonmedical (nutrition, home care, transporta-
tion), and indirect costs [45]. Finally, the cost basis used for
Colombia relies on hospitalizations only; these estimates were
derived from the 2005 monthly clinical report from Renal
Therapy Services, a network of renal clinics in Colombia and
include costs associated with any hospitalization event for
patients on PD and HD.
Results
Modeled results show projected modality use and budget impacts
(payer perspective) for each country (Table 3). These results
should be read together with the country-speciﬁc estimates pro-
vided in Tables 1 and 2. Taking a detailed look at the UK as one
example, we see that, as of June 2007, there were an estimated
25,628 patients on dialysis in the UK and the ratio of HD : PD
utilization was 79:21 (Table 1). The assumption is that this popu-
lation would grow by 5% annually and that the average point-
prevalent patient would receive 12 months of dialysis annually
(Table 1). If over 5 years there were to be a shift in dialysis
modality use to 30% PD and 70% HD (Table 3) and assuming
costs are as estimated in Table 2, the model projects that the
cumulative national savings for dialysis services would be about
£133 million (2007 £). These savings would create an opportu-
nity to provide an additional 4495 patient-years of dialysis treat-
ment within a ﬁxed national budget for dialysis treatment
(Table 3).
Analogously, model results for Singapore, a relatively small
country with a baseline prevalent dialysis population of fewer
than 4000 individuals in 2006, project that a shift in PD use from
the current 21% to 40% over a period of 5 years would create
the opportunity to provide an additional 919 patient-years of
dialysis treatment. Similarly, increasing PD use in Chile from its
current 6% to 25% over 5 years would provide some 901 addi-
tional patient-years of dialysis treatment within a ﬁxed national
Table 1 Dialysis demand and baseline modality use
UK* Singapore† Mexico‡ Chile§ Romania Thailand¶ China# Colombia**
Baseline year 2007 2006 2006 2005 2006 2005 2005 2005
Prevalent dialysis population
Baseline 25,628 3,953 47,483 11,361 7,060 12,900 74,137 7,441
Projected annual growth (%) 5.0 7.8 9.0 9.0 10 10.0 10.0 8.0
Patient-years at risk 1.00 0.72 0.72 1.00 0.72 0.72 0.72 1.00
Baseline modality use
HD : PD 79:21 79:21 24:76 94:6 82:18 93:7 89:11 57:43
Source citation(s):
*[78].
†[71–73].
‡[10,48,79–82].
§[4,83,84].
[85].
¶[4,75,86].
#[45,87].
**[83,88–90].
HD, hemodialysis; PD, peritoneal dialysis.
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dialysis budget. A seven percentage point increase in PD utiliza-
tion over 5 years in Romania (from 18% to 25%) would enable
the country’s current dialysis budget to cover an additional 741
patient life-years of treatment, and parallel nine percentage point
increase in PD utilization in Thailand (from 11% to 20%) would
allow funding for an additional 677 patient-years of dialysis
without an increase in current national spending.
In Mexico and China, where the baseline prevalent dialysis
populations exceed 47,000 and 74,000 individuals, respectively,
even relatively modest increases in PD use (from 76% to 81% in
Mexico and from 11% to 21% in China) would yield substantial
savings, enough to support nearly 3500 (Mexico) and 3900
(China) additional patient-years of treatment within each coun-
try’s baseline dialysis budget.
Modeled results in Colombia reﬂect the cost of hospitaliza-
tions only. As of 2005 there were an estimated 7441 patients on
dialysis in Colombia, 43% of which were on PD (80% CAPD).
The number of patients on dialysis was growing at 8% per year.
Costs per hospitalization event were $2144, $884, and $775 for
patients on HD, APD, and CAPD, respectively (2006 $). If over
5 years PD use were to increase by 5% (to 48% PD), hospital-
ization costs would decrease by $2.3 million, or the equivalent of
1546 patient-years of hospital events.
Sensitivity Analyses
A variety of one-way sensitivity analyses were conducted to
explore model forecasts under varying assumptions about ESRD
growth rates and years to reach targeted proportions of dialysis
modality use. In general, results of these analyses demonstrate
that modeled cumulative 5-year savings are sensitive to time;
speciﬁcally, that savings will be greater as the shift toward greater
PD use is accomplished sooner. The model is sensitive to assump-
tions about projected growth in ESRD populations; higher
growth rates will result in greater cumulative savings as PD use
increases, although the savings may still be substantial in a given
country even if growth in ESRD populations is lower than antici-
pated. The model also projects greater savings as expenditures
for PD decrease relative to HD. In general, countries with large
prevalent dialysis populations, high ESRD growth rates and/or
low baseline utilization of PD stand to gain the most from
increasing clinically appropriate use of PD. Conversely, the
model predicts that cumulative 5-year spending for dialysis in
any given country will increase as time to reach projected PD
modality use increases, as the costs associated with PD increase
relative to HD and as PD utilization declines.
Discussion
Worldwide, the systems costs of treating ESRD patients are of a
large magnitude. Financial and reimbursement issues have been
identiﬁed as the most important nonmedical factors in dialysis
modality selection in any given country, and the growing ESRD
population underscores the importance of these issues [8,9,40]. It
is in the best interest of governments and health-care decision-
makers to direct spending toward the most cost-efﬁcient method
of dialysis treatment for ESRD. Research reports from Eastern
and Western Europe suggest that PD costs are similar to, or lower
than HD costs [41–43,70,76]. And although PD is often per-
ceived to be more expensive than HD in developing countries
because of relatively low costs of labor and space compared with
high costs of imported supplies, several published analyses
disavow this perception, showing that PD treatment is, in
fact, often less expensive than HD in the developing world
[41,44,46,47,74,77]. Further, whereas delivery of HD is largelyTa
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dependent on the availability of trained nurses and other dialysis
personnel, PD is a home-based therapy that is performed inde-
pendently by the patient—an especially important consideration
in areas where trained HD workers are in short supply. In addi-
tion, PD requires very little in terms of physical resources com-
pared to HD, such as building space, water puriﬁcation,
electricity, and the purchase and maintenance of expensive HD
equipment. Yet global utilization of PD relative to HD remains
low, despite its clinical and economic advantages.
We used a budget impact model to consider the extent to
which shifting the mix of dialysis modalities toward greater use
of clinically-appropriate PD might reduce the ﬁnancial burden of
caring for an expanding ESRD population and/or maximize the
level of dialysis services that a ﬁxed health-care budget is able to
support. The results suggest that, in countries where the systems
cost of providing PD is lower than HD, an increased use of
clinically appropriate PD provides an opportunity to substan-
tially lower overall ESRD treatment costs. These savings could be
applied to reduce health-care costs in the dialysis population
or to treat additional patients with ESRD or other debilitating
conditions.
Our analysis has a number of limitations. Although our budget
impact model presents ﬁnancial streams over time, it does not
include inﬂation or discounting. Costs are assumed to remain
constant over the time horizon of each analysis, and do not include
costs associated with transplantation, physical facilities and
equipment, training, or patients’ switching from one mode of
dialysis to another. Indeed, the initial investment necessary to
achieve increased use of PD would likely vary by country, because
infrastructures differwidely and barriers to PDusemay be, in part,
socially determined. Projected shifts in the use of PD relative to
HD are assumed in the model to occur linearly over time;
increased savings would result to the extent that the projected
modality shift occurred sooner, rather than later over the modeled
time horizon. The cost basis used in this analysis varies among
countries, making between-country comparisons imprecise.
Because some of the country-speciﬁc baseline inputs used in the
model is only available as abstracts, the results must be interpreted
with caution; additional research is needed to conﬁrm these
assumptions in other regions of the world. In addition, full
economic evaluations assess costs and outcomes, where outcomes
are measured in dollars (cost-beneﬁt analysis), units of a desirable
end point such as life-years saved (cost-effectiveness analysis), or
years of life gained adjusted by a measure of life quality (cost-
utility analysis). The majority of published studies comparing
dialysis modalities have focused solely on costs, rather than
cost-effectiveness or cost-utility [41,76]. In part this may be
because survival and quality of life outcomes for HD and PD are
generally considered to be similar [41]. Cost analyses are consid-
ered useful for macro-level ﬁscal planning. Nevertheless, it should
be noted that, although PD and HD are complementary therapies,
they are not perfect substitutes. Preferences for dialysis modalities
may differ when outcomes are taken into consideration, rather
than solely focusing on costs. Despite the simplicity of the model
and its inherent limitations, it is an important starting point. The
magnitude of the potential savings warrants further investigation
and discussion of these important topics.
Conclusions
The systems costs of treating ESRD patients are large and increas-
ing, and there is little doubt that the funding of treatment for the
ESRD population already creates signiﬁcant ﬁnancial challenges
across the globe. The growing ESRD population and the high cost
of renal replacement therapies underscore the importance of these
issues. Nations should look more closely at modes of dialysis that
are both clinically effective and cost-saving. There is evidence
suggesting that PD therapy is signiﬁcantly cost-saving compared
to HD therapy, even in developing countries. In countries where
the systems cost of providing PD is lower than HD, an increased
use of clinically appropriate PD provides an opportunity to sub-
stantially lower overall ESRD treatment costs. The considerable
cumulative savings that would stem from increased use of PD over
time could be used to offset part of the ﬁnancial burden of ESRD
care and help nations respond to ever-tightening health-care
budget constraints. The sheer magnitude of the potential savings
warrants a more in-depth, country-speciﬁc evaluation of these
issues. At the very least, nations should take care to prevent any
negative incentives to usingmore cost-efﬁcientmethods of treating
a costly and increasingly prevalent chronic disease.
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